Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol
A 42-year-old female with telomeropathy-related interstitial lung disease experienced dramatic improvement in respiratory failure and lung function with immunosuppression and danazol treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper describes a single 39-year-old patient with rapidly progressive interstitial lung disease (non-specific interstitial pneumonia on open lung biopsy) and extrapulmonary findings including finger clubbing that had earlier resolved during pregnancy; telomere-related disease was suspected based on premature greying in the patient’s personal and family history and very short peripheral blood monocyte telomere length (<1st centile). After starting immunosuppression with prednisolone and mycophenolate mofetil, the patient showed modest improvement, and danazol was then added due to reported telomere-lengthening effects of the synthetic androgen and the pregnancy-associated reversal of clubbing; over 18 months, danazol was associated with marked clinical, radiological, and physiological recovery and normalization of telomere length (>10th centile), allowing immunosuppression tapering. The major limitation is that this is a case report, so causal attribution and generalizability cannot be established. Relevance to endometriosis: the patient’s untreated endometriosis is mentioned in the history, though the paper’s main focus is telomereopathy-related interstitial lung disease treatment and its relationship to telomere biology.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
7,509 characters
· extracted from
pmc-nxml
· 3 sections
· click to expand
Case
Discussion
Introduction
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (2)
- Danazol Treatment for Telomere Diseases 2016
- Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol 2020
Cited by (3)
- Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol 2020
- TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis 2021
- No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis 2023
References (6)
- Danazol Treatment for Telomere Diseases via openalex
- Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol via openalex
- doi:10.1183/13993003.01641-2018 via openalex
- doi:10.1182/blood-2008-09-178871 via openalex
- doi:10.1164/rccm.201112-2175im via openalex
- doi:10.1378/chest.14-3078 via openalex
Cited by (3)
- No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis 2023
- TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis 2021
- Successful treatment of telomeropathy‐related interstitial lung disease with immunosuppression and danazol 2020
Source provenance
- europepmc
- last seen: 2026-07-02T06:07:54.402228+00:00
- openalex
- last seen: 2026-05-11T04:48:31.490805+00:00